Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

FX-06

😃Good
Catalog No. T78562Cas No. 88650-17-3
Alias Fibrin-derived peptide Bβ15-42

FX-06 (Fibrin-derived peptide Bβ15-42) is derived from the fibrin Bbeta chain and interacts with VE-cadherin to inhibit leukocyte transmigration while initiating VE-cadherin-mediated signaling pathways. This compound is utilized in researching ischemia/reperfusion injury and Dengue shock syndrome (DSS) [1] [2] [4].

FX-06

FX-06

😃Good
Catalog No. T78562Alias Fibrin-derived peptide Bβ15-42Cas No. 88650-17-3
FX-06 (Fibrin-derived peptide Bβ15-42) is derived from the fibrin Bbeta chain and interacts with VE-cadherin to inhibit leukocyte transmigration while initiating VE-cadherin-mediated signaling pathways. This compound is utilized in researching ischemia/reperfusion injury and Dengue shock syndrome (DSS) [1] [2] [4].
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
5 mgInquiry8-10 weeks8-10 weeks
50 mgInquiry8-10 weeks8-10 weeks
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
FX-06 (Fibrin-derived peptide Bβ15-42) is derived from the fibrin Bbeta chain and interacts with VE-cadherin to inhibit leukocyte transmigration while initiating VE-cadherin-mediated signaling pathways. This compound is utilized in researching ischemia/reperfusion injury and Dengue shock syndrome (DSS) [1] [2] [4].
In vitro
FX-06 (50 μM, 3 days) inhibits D2HG synthesis in HEK-293T cells expressing mutant IDH1 R132H [2].
In vivo
FX06, administered intravenously at 2.4 mg/kg as a bolus, notably enhances pulmonary and circulatory function in a porcine model of hemorrhagic shock and reperfusion [3]. The same dosage, given intraperitoneally twice daily, increases survival rates and mitigates capillary leakage in Dengue shock syndrome mouse models [4]. When administered at 3.6 mg/kg intravenously, FX06 safeguards against ischemia/reperfusion (I/R)-induced renal damage in mice, promoting epithelial cell proliferation and facilitating tissue repair [5].
SynonymsFibrin-derived peptide Bβ15-42
Chemical Properties
Molecular Weight3039.41
FormulaC133H216N44O38
Cas No.88650-17-3
SmilesC(=O)(N1[C@H](C(=O)N2[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(NCC(N[C@@H](CC3=CC=C(O)C=C3)C(N[C@@H](CCCNC(=N)N)C(O)=O)=O)=O)=O)=O)=O)CO)=O)[C@H](CC)C)=O)CCC2)CCC1)[C@H]4N(C([C@@H](NC(=O)[C@H]5N(C([C@@H](NC([C@@H](NC([C@@H](NC(=O)[C@H]6N(C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(=O)[C@H]7N(C([C@@H](NC([C@H](CC8=CN=CN8)NC(CN)=O)=O)CCCNC(=N)N)=O)CCC7)CC(C)C)=O)CC(O)=O)=O)CCCCN)=O)CCCCN)=O)CCCNC(=N)N)=O)CCC(O)=O)=O)CCC(O)=O)=O)C)=O)CCC6)CO)=O)CC(C)C)=O)CCCNC(=N)N)=O)CCC5)C)=O)CCC4
SequenceGly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg
Sequence ShortGHRPLDKKREEAPSLRPAPPPISGGGYR
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy FX-06 | purchase FX-06 | FX-06 cost | order FX-06 | FX-06 chemical structure | FX-06 in vivo | FX-06 in vitro | FX-06 formula | FX-06 molecular weight
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.